Celebrex, NSAID Labeling Must Include Skin Reactions Warning, FDA Says
Executive Summary
FDA is requiring labeling for non-steroidal anti-inflammatory drugs include a warning on skin reactions, in addition to a boxed warning on cardiovascular and gastrointestinal risk
You may also be interested in...
NSAID Panel Highlights Challenge Of Getting Comparative Safety Claim
Does wide public health concern warrant flexibility in regulatory standards for safety claims? Advisory panel on cardiovascular risk of NSAIDs spotlights dual challenge of accurately determining drug risks and communicating risks in informative way.
NSAID Panel Highlights Challenge Of Getting Comparative Safety Claim
Does wide public health concern warrant flexibility in regulatory standards for safety claims? Advisory panel on cardiovascular risk of NSAIDs spotlights dual challenge of accurately determining drug risks and communicating risks in informative way.
NSAID Safety Review: FDA Panel Seeks Continued PRECISION From Pfizer
Pfizer’s long-term safety outcome study comparing Celebrex, ibuprofen and naproxen has its flaws, but FDA advisory committee says its data will be far superior to meta-analyses or observational studies.